华润医疗(01515.HK)拟收购江苏省一间营利性医院
格隆汇 3 月 28日丨华润医疗(01515.HK)发布公告，2021年3月28日，江华管理(公司的全资附属公司)与售股股东、卖方及Sinophi Hospitals订立股份购买协议。根据股份购买协议，江华管理有条件同意收购而卖方有条件同意出售销售股份(亦即Sinophi Hospitals的控股股权)，代价为人民币8.83亿元。于本公告日期，Sinophi Hospitals间接持有淮阴医院80%股权，淮阴医院为一间位于江苏省淮安市的营利性综合医院，其开放床位数约为1,190床。
公告表示，收购事项有助于集团获取稀缺的医疗业务资源，并将作为集团开启长三角区域医疗业务拓展布局的起点。淮阴医院位于长三角地区江苏省淮安市，是淮安市淮阴区唯一一所具备等级的医院，作为该区的龙头医院拥有占该区内近39%的住院服务市场份额，其在医疗技术水准、医院品牌口碑、政府认可程度等方面都积累了较好的基础。淮阴医院作为区内转诊的唯一入口，也是获取区内基层诊疗流量的核心渠道，具备区内其他医疗机构难以复制的竞争优势。淮阴医院已于两年前完成营利性改制，其产权归属清晰、经营状况良好、管理规范有序，是近年来市场中较为稀缺的优质医疗业务资源。集团在长三角地区暂无具规模的医疗机构布局，而收购事项将为集团在长三角地区获取一所拥有逾1,000个开放床位、年门急诊量逾45万人次的二级甲等营利性综合医院，实为集团落子长三角区域的关键举措，并将成为集团未来在长三角进一步扩大医疗服务业务布局的起点。
另外，集团亦拟于淮阴医院打造“大专科小综合”的业务模式。考虑到淮阴医院当前外科基础良好，特别是其骨科已基具备三级医院技术水准，集团将借助医院二期工程新增住院空间的契机，聚焦打造以关节和脊柱外科为骨科特色的专业科室，精益求精以形成该医院突出的专科特色。同时，集团亦将引入旗下三九脑科医院的医疗资源，在神经内科方面针对性提升淮阴医院脑血管病的综合诊治水准，并在神经外科方面重点提升神经外科急症的综合诊治水准、加快培育具竞争力的针对特定病种能力，为淮阴医院提供新的增长点与专科竞争力，与区域内的公立医院形成差异化发展，打造“大专科小综合”发展模式，并借此进一步整合区内医疗服务资源，扩大市场份额，巩固区域领先的竞争地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
